Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12794521rdf:typepubmed:Citationlld:pubmed
pubmed-article:12794521lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:12794521lifeskim:mentionsumls-concept:C0079459lld:lifeskim
pubmed-article:12794521lifeskim:mentionsumls-concept:C0023452lld:lifeskim
pubmed-article:12794521lifeskim:mentionsumls-concept:C0150099lld:lifeskim
pubmed-article:12794521pubmed:issue6lld:pubmed
pubmed-article:12794521pubmed:dateCreated2003-6-9lld:pubmed
pubmed-article:12794521pubmed:abstractTextIn a previous randomized study, the authors reported that granulocyte colony-stimulating factor (G-CSF) increased the chemotherapy dose-intensity delivered during the consolidation therapy of high-risk childhood acute lymphoblastic leukemia (ALL). The aim of the current study was to perform an economic evaluation in the same cohort.lld:pubmed
pubmed-article:12794521pubmed:languageenglld:pubmed
pubmed-article:12794521pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12794521pubmed:citationSubsetIMlld:pubmed
pubmed-article:12794521pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12794521pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12794521pubmed:statusMEDLINElld:pubmed
pubmed-article:12794521pubmed:monthJunlld:pubmed
pubmed-article:12794521pubmed:issn1077-4114lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:BerthouChrist...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:VannierJean-P...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:LeblancThierr...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:BordigoniPier...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:GandemerVirgi...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:LevergerGuyGlld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:BaruchelAndré...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:BraguerDianeDlld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:PerelYvesYlld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:LamagnereJean...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:MichelGérardGlld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:AuclercMarie-...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:DelormeJeanJlld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:BadinStéphani...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:Le...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:AuvrignonAnne...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:DemeocqFranço...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:BauduerFranço...lld:pubmed
pubmed-article:12794521pubmed:authorpubmed-author:PautardBrigit...lld:pubmed
pubmed-article:12794521pubmed:issnTypePrintlld:pubmed
pubmed-article:12794521pubmed:volume25lld:pubmed
pubmed-article:12794521pubmed:ownerNLMlld:pubmed
pubmed-article:12794521pubmed:authorsCompleteYlld:pubmed
pubmed-article:12794521pubmed:pagination441-7lld:pubmed
pubmed-article:12794521pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:meshHeadingpubmed-meshheading:12794521...lld:pubmed
pubmed-article:12794521pubmed:year2003lld:pubmed
pubmed-article:12794521pubmed:articleTitleEconomic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia.lld:pubmed
pubmed-article:12794521pubmed:affiliationDepartment of Pharmacy, Research Unit INSERM No. 379, France.lld:pubmed
pubmed-article:12794521pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12794521pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12794521pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12794521pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12794521pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:12794521pubmed:publicationTypeEvaluation Studieslld:pubmed